| 1 | video journal of biomedicine | | | | | | | 3 | 0.96% |
| 2 | immunologyimmunotherapy tezepelumab for severe | | | | | | | 2 | 0.64% |
| 3 | followup of a phase | | | | | | | 2 | 0.64% |
| 4 | interferon beta1a therapy for | | | | | | | 2 | 0.64% |
| 5 | subcutaneous interferon beta1a therapy | | | | | | | 2 | 0.64% |
| 6 | support of adherence to | | | | | | | 2 | 0.64% |
| 7 | to improve usability in | | | | | | | 2 | 0.64% |
| 8 | phild the increase study | | | | | | | 2 | 0.64% |
| 9 | autoinjector to improve usability | | | | | | | 2 | 0.64% |
| 10 | people living with multiple | | | | | | | 2 | 0.64% |
| 11 | oct 2023 cardiopulmonaryvascular inhaled | | | | | | | 2 | 0.64% |
| 12 | 19 oct 2023 cardiopulmonaryvascular | | | | | | | 2 | 0.64% |
| 13 | extended followup of a | | | | | | | 2 | 0.64% |
| 14 | xevinapantchemoradiotherapy in la scchn | | | | | | | 2 | 0.64% |
| 15 | the evolution of the | | | | | | | 2 | 0.64% |
| 16 | with palbociclib plus aromatase | | | | | | | 2 | 0.64% |
| 17 | evaluation of overall survival | | | | | | | 2 | 0.64% |
| 18 | about us expert advisory | | | | | | | 2 | 0.64% |
| 19 | us expert advisory panel | | | | | | | 2 | 0.64% |
| 20 | expert advisory panel author | | | | | | | 2 | 0.64% |
| 21 | in hrher2 metastatic breast | | | | | | | 2 | 0.64% |
| 22 | advisory panel author guidelines | | | | | | | 2 | 0.64% |
| 23 | of the evolution of | | | | | | | 2 | 0.64% |
| 24 | inhibitor in hrher2 metastatic | | | | | | | 2 | 0.64% |
| 25 | summary of the evolution | | | | | | | 2 | 0.64% |
| 26 | 2022 animated videos propensity | | | | | | | 1 | 0.32% |
| 27 | 28 sep 2023 oncologyhematology | | | | | | | 1 | 0.32% |
| 28 | sep 2023 oncologyhematology safety | | | | | | | 1 | 0.32% |
| 29 | matching methodology why and | | | | | | | 1 | 0.32% |
| 30 | 2023 oncologyhematology safety and | | | | | | | 1 | 0.32% |
| 31 | efficacy darolutamide in blackafricanamerican | | | | | | | 1 | 0.32% |
| 32 | darolutamide in blackafricanamerican patients | | | | | | | 1 | 0.32% |
| 33 | in blackafricanamerican patients in | | | | | | | 1 | 0.32% |
| 34 | dec 2022 animated videos | | | | | | | 1 | 0.32% |
| 35 | blackafricanamerican patients in the | | | | | | | 1 | 0.32% |
| 36 | patients in the aramis | | | | | | | 1 | 0.32% |
| 37 | methodology why and how | | | | | | | 1 | 0.32% |
| 38 | why and how it | | | | | | | 1 | 0.32% |
| 39 | animated videos propensity score | | | | | | | 1 | 0.32% |
| 40 | 13 dec 2022 animated | | | | | | | 1 | 0.32% |